Atlas Trials

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Clinical trial NCT03486496 · UNKNOWN

Trial details

NCT number
NCT03486496
Sponsor
Fujian Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Lung AdenocarcinomaEGFR Mutation
Start date
2018-06-05
Primary completion
2019-06-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.